Exubera Adoption Not Recommended By U.K. Cost-Effectiveness Group
This article was originally published in The Pink Sheet Daily
Executive Summary
The National Institute for Health & Clinical Excellence says it needs more evidence on Pfizer’s inhaled insulin before it can recommend NHS coverage.